Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Targeting sarbecoviruses As we continue to battle the COVID-19 pandemic, we must confront the possibility of new pathogenic coronaviruses emerging… Read More »Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Variant-proof vaccines — invest now for the next pandemic
The rapid development and delivery of highly effective COVID-19 vaccines less than a year after the emergence of the disease… Read More »Variant-proof vaccines — invest now for the next pandemic
COVID-19 antibodies on trial
Linda J. Saif is at the Ohio Agricultural Research and Development Center at The Ohio State University College of Veterinary… Read More »COVID-19 antibodies on trial
Structural basis of a shared antibody response to SARS-CoV-2
Structural basis of a shared antibody response to SARS-CoV-2 A common theme in antibody response. In the fight against severe… Read More »Structural basis of a shared antibody response to SARS-CoV-2
Isolation of potent SARS- CoV-2 neutralizing antibodies and protection from disease in a small animal model
Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first… Read More »Isolation of potent SARS- CoV-2 neutralizing antibodies and protection from disease in a small animal model
Broad neutralization of SARS-related viruses by human monoclonal antibodies
Seeking broad protection As scientists develop therapeutic antibodies and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the risk… Read More »Broad neutralization of SARS-related viruses by human monoclonal antibodies